Clinical value of sST2 in replacement of NT-proBNP in cardiac function evaluation in renal failure patients after cardiac surgery_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

 ZHAO Dong ¹ , WU Bo ² , SHEN Jinqiang ¹ , WANG Chunsheng ¹

1. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China;
2. Department of Cardiology, Yangpu Hospital, Tongji University, Shanghai, 200082, P.R.China;

Corresponding author：

ZHAO Dong, Email: eastzhao15@126.com

Keywords：

Soluble suppression of tumorigenesis-2 (sST2); N-terminal fragment of the brain natriuretic peptide precursor (NT-proBNP); cardiac function index; perioperative period; surgery

DOI：

10.7507/1007-4848.202003006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the clinical value of soluble suppression of tumorigenesis-2 (sST2) in replacement of N-terminal fragment of the brain natriuretic peptide precursor (NT-proBNP) in cardiac function evaluation in renal failure patients after cardiac surgery.Methods Sixty patients with renal insufficiency after cardiac surgery from January 2019 to June 2019 were divided into a test group, including 34 males and 26 females, with an average age of 49-78 (63.3±4.5) years. Another 60 patients with normal renal function were divided into a control group, including 37 males and 23 females, with an average age of 53-77 (61.7±3.8) years. The perioperative left ventricular ejection fraction, cardiac troponin T, creatine kinase-MB, sST2 and NT-proBNP were compared.Results In patients of the test group, the NT-proBNP level increased significantly during perioperative period, and the change range was different from other cardiac function indexes. The change of sST2 in perioperative period was similar to other cardiac function indexes, which could reflect the change degree of cardiac function after operation.Conclusion sST2 is more important to reflect the change degree of cardiac function in patients with renal dysfunction after cardiac surgery than NT-proBNP.

Citation： ZHAO Dong, WU Bo, SHEN Jinqiang, WANG Chunsheng. Clinical value of sST2 in replacement of NT-proBNP in cardiac function evaluation in renal failure patients after cardiac surgery. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(3): 331-334. doi: 10.7507/1007-4848.202003006 Copy

1.	Song Y, Li F, Xu Y, et al. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol, 2020, 304: 95-100.
2.	Polineni S, Parker DM, Alam SS, et al. Predictive ability of novel cardiac biomarkers ST2, Galectin-3, and NT-ProBNP before cardiac surgery. J Am Heart Assoc, 2018, 7(14): e008371.
3.	Franeková J, Hošková L, Sečník PJ, et al. The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation. Clin Chem Lab Med, 2016, 54(2): 339-344.
4.	Dörr O, Walther C, Liebetrau C, et al. Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). Clin Cardio, 2018, 41(9): 1164-1169.
5.	Wernly B, Lichtenauer M, Jirak P, et al. Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation. Eur J Clin Invest, 2017, 47(2): 149-157.
6.	Jabagi H, Mielniczuk LM, Liu PP, et al. Biomarkers in the diagnosis, management, and prognostication of perioperative right ventricular failure in cardiac surgery—Are we there yet? J Clin Med, 2019, 8(4): 559.
7.	Tseng CCS, Huibers MMH, Gaykema LH, et al. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device. Eur J Clin Invest, 2018, 48(3): e12886.
8.	Stundl A, Lünstedt NS, Courtz F, et al. Soluble ST2 for risk stratification and the prediction of mortality in patients undergoing transcatheter aortic valve implantation. Am J Cardiol, 2017, 120(6): 986-993.
9.	Bekos C, Zimmermann M, Unger L, et al. Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal function. Sci Rep, 2016, 6: 32315.
10.	Crnko S, Printezi MI, Jansen TPJ, et al. Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Fail, 2020, 7(3): 1224-1233.
11.	Beaudoin J, Singh JP, Szymonifka J, et al. Novel heart failure biomarkers predict improvement of mitral regurgitation in patients receiving cardiac resynchronization therapy —The BIOCRT Study. Can J Cardio, 2016, 32(12): 1478-1484.
12.	Galeone A, Lessana A, Mascolo E, et al. Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation. Thorac Cardiovasc Surg, 2014, 62(1): 47-51.

1. Song Y, Li F, Xu Y, et al. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol, 2020, 304: 95-100.
2. Polineni S, Parker DM, Alam SS, et al. Predictive ability of novel cardiac biomarkers ST2, Galectin-3, and NT-ProBNP before cardiac surgery. J Am Heart Assoc, 2018, 7(14): e008371.
3. Franeková J, Hošková L, Sečník PJ, et al. The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation. Clin Chem Lab Med, 2016, 54(2): 339-344.
4. Dörr O, Walther C, Liebetrau C, et al. Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip). Clin Cardio, 2018, 41(9): 1164-1169.
5. Wernly B, Lichtenauer M, Jirak P, et al. Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation. Eur J Clin Invest, 2017, 47(2): 149-157.
6. Jabagi H, Mielniczuk LM, Liu PP, et al. Biomarkers in the diagnosis, management, and prognostication of perioperative right ventricular failure in cardiac surgery—Are we there yet? J Clin Med, 2019, 8(4): 559.
7. Tseng CCS, Huibers MMH, Gaykema LH, et al. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device. Eur J Clin Invest, 2018, 48(3): e12886.
8. Stundl A, Lünstedt NS, Courtz F, et al. Soluble ST2 for risk stratification and the prediction of mortality in patients undergoing transcatheter aortic valve implantation. Am J Cardiol, 2017, 120(6): 986-993.
9. Bekos C, Zimmermann M, Unger L, et al. Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal function. Sci Rep, 2016, 6: 32315.
10. Crnko S, Printezi MI, Jansen TPJ, et al. Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Fail, 2020, 7(3): 1224-1233.
11. Beaudoin J, Singh JP, Szymonifka J, et al. Novel heart failure biomarkers predict improvement of mitral regurgitation in patients receiving cardiac resynchronization therapy —The BIOCRT Study. Can J Cardio, 2016, 32(12): 1478-1484.
12. Galeone A, Lessana A, Mascolo E, et al. Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation. Thorac Cardiovasc Surg, 2014, 62(1): 47-51.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Clinical value of sST2 in replacement of NT-proBNP in cardiac function evaluation in renal failure patients after cardiac surgery

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content